Baseline subject characteristics in progressors, and non-progressors on X-ray
| Variable | X-ray progressors 52 weeks (n=68) | X-ray non-progressors 52 weeks (n=187) | p Value |
|---|---|---|---|
| Age (years) | 47.8 (11.4) | 48.7 (12.48) | 0.6 |
| Female, n (%) | 54 (79) | 158 (84) | 0.3 |
| Disease duration (years) | 3.59 (0.86) | 3.09 (4.80) | 0.5 |
| Methotrexate, n (%) | 21 (31) | 45 (24) | 0.5 |
| Golimumab, n (%) | 14 (21) | 47 (25) | |
| MTX+GLM 50 mg, n (%) | 14 (21) | 50 (27) | |
| MTX+GLM 100 mg, n (%) | 19 (28) | 45 (24) | |
| CCP Positive, n (%) | 58 (85) | 137 (73) | 0.05 |
| Baseline DAS28(CRP) | 5.79 (1.10) | 5.56 (1.06) | 0.1 |
| Baseline vdHS | 8 [2.5, 25.25] | 4.5 [2, 15] | <0.001 |
Data are presented as mean (SD) and median [IQR] (for skewed data).
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28(CRP), Disease Activity Score 28 with CRP; GLM, golimumab; MTX, methotrexate; vdHS, van der Heijde–Sharp.